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Abstract: Replication and maintenance of mtDNA entirely relies on a set of proteins encoded by 
the nuclear genome, which include members of the core replicative machinery, proteins involved 
in the homeostasis of mitochondrial dNTPs pools or deputed to the control of mitochondrial 
dynamics and morphology. Mutations in their coding genes have been observed in familial and 
sporadic forms of pediatric and adult-onset clinical phenotypes featuring mtDNA instability. The 
list of defects involved in these disorders has recently expanded, including mutations in the  
exo-/endo-nuclease flap-processing proteins MGME1 and DNA2, supporting the notion that an 
enzymatic DNA repair system actively takes place in mitochondria. The results obtained in the 
last few years acknowledge the contribution of next-generation sequencing methods in the 
identification of new disease loci in small groups of patients and even single probands. Although 
heterogeneous, these genes can be conveniently classified according to the pathway to which 
they belong. The definition of the molecular and biochemical features of these pathways might 
be helpful for fundamental knowledge of these disorders, to accelerate genetic diagnosis of 
patients and the development of rational therapies. In this review, we discuss the molecular 
findings disclosed in adult patients with muscle pathology hallmarked by mtDNA instability. 
Keywords: mtDNA maintenance; multiple mtDNA deletions; adult mitochondrial disorders; 
progressive external ophthalmoplegia; mitochondrial myopathy 
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1. Introduction 
Mitochondrial disorders display heterogeneous clinical presentations in terms of age at onset, 
progression and symptoms. This variability reflects their complex pathogenesis, which might affect 
structural proteins and enzymes involved in oxidative metabolism, finally leading to the mitochondrial 
dysfunction observed in multiple cell types and tissues [1]. 
Serum abnormalities (i.e., increased lactate levels) or evidence of respiratory chain impairment  
in affected tissues (i.e., isolated or combined complex deficiency) are often indicative of inadequate 
mitochondrial respiration, although they are not observed in many primary mitochondrial disorders [2]. 
Moreover, they lack specificity or should be tested in inaccessible tissues, jeopardizing their efficacy 
in a clinical setting. Therefore, clinical variability and the unavailability of reliable biomarkers delay 
the diagnosis in early- and late-onset mitochondrial disorders. 
In adult non-syndromic clinical presentations, the involvement of skeletal muscle is mainly 
exhibited by external ophthalmoplegia, isolated or accompanied by limb weakness [3]. In these patients, 
histological studies on muscle biopsy usually reveal the presence of fibers not reacting to cytochrome c 
oxidase staining (COX-negative fibers) or showing signs of compensatory mitochondrial proliferation 
(ragged-red fibers) [4]. Southern blot analysis of muscle-extracted mitochondrial DNA (mtDNA) can 
detect reduced mtDNA content and multiple deletions, reflecting mtDNA instability [5]. Although subtle 
mtDNA deletions can accumulate in the muscle of patients harboring mtDNA point mutations [6], they 
are largely considered hallmarks of adult disorders due to defects in nuclear genes. Therefore, the 
disclosure of these alterations is helpful to identify a specific subgroup of mitochondrial disorders 
(multiple mtDNA deletions syndromes), but the large number of imputable genes hampers the chance of 
a prompt molecular diagnosis, especially in sporadic cases. 
In 2000, missense mutations in SLC25A4 (encoding for the mitochondrial translocator ANT1) have 
been identified as the first molecular defects resulting in impaired mtDNA maintenance in human [7]. 
Since then, the hunt for molecular defects underlying multiple mtDNA deletion syndromes has 
demonstrated to be a very active field of research contributing to improving the diagnostic yield of 
these conditions. At the same time, these studies expanded our knowledge of the proteins involved in the 
replication and repair of the mitochondrial genome. Some of these proteins were found to have 
multiple, sometimes redundant activities, while others seem to have unique functions [8]. 
In this review, we overview the genes hosting mutations linked with adult-onset phenotypes 
featuring the accumulation of mtDNA deletions in skeletal muscle. The limited number of patients 
harboring mutations in the most recently-described genes prevents the definition of clear  
genotype-phenotype correlations, which are still elusive, even for the most frequent genetic defects. 
However, the systematic collection of clinical and molecular data of diagnosed patients might help to 
disclose features shared by subjects harboring mutations in the same gene or pathway. 
2. Molecular Features in Adult Mitochondrial Disorders Featuring Muscle mtDNA Instability 
Disturbances of mtDNA homeostasis result in clinical presentations affecting every stage of life. 
Infantile and pediatric forms are mostly associated with a strong reduction of mtDNA content in 
affected tissues; therefore, they are collectively termed mtDNA depletion syndromes [9]. The low 
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residual mtDNA levels cannot sustain a proper respiratory chain assembly: the resulting dysfunction 
mainly impacts complexes containing mtDNA-encoded subunits and spares complex II, which is 
entirely encoded by nuclear DNA. 
In adults, large-scale deletions of mtDNA spontaneously accumulate in post-mitotic tissues with 
ageing [6]. The position and extension of such deletions within the mitochondrial genome may be 
heterogeneous, and in most cases, their accumulation does not result in clinical presentations, although 
a biochemical defect could be observed by histochemical or enzymatic studies. These slight alterations 
might also be involved in muscle weakness naturally occurring with ageing. On the opposite side, in 
primary mitochondrial disorders due to impaired mtDNA maintenance, deletions tend to accumulate  
in post-mitotic tissues (i.e., muscle) and result in clinical phenotypes, even in relatively young  
subjects [10]. These alterations are easily detectable on muscle-extracted DNA specimens using 
Southern blot analysis and standard or quantitative PCR protocols. The co-existence of a quantitative 
(depletion) and qualitative (deletions) alteration of mtDNA in the same patient is not excluded. 
Both pediatric and adult-onset presentations due to mtDNA instability originate from molecular 
defects in nuclear genes. This is relevant for human health, since such disorders are transmitted 
according to Mendelian inheritance. Infantile- or juvenile-onset mtDNA depletion syndromes are 
associated with recessive mutations, resulting in the loss of function of the encoded enzymes. Adult 
presentations are genetically more heterogeneous, presenting both recessive and dominant types of 
transmission, these two forms co-existing even for the same gene [11] (Figure 1). 
 
Figure 1. Schematic overview of the proteins and pathways involved in mtDNA 
maintenance. Zooming in on the mtDNA allows the identification of factors involved in 
mtDNA replication and repair (A) including: POLG, Twinkle, DNA2, MGME1; on the 
right (B) are the proteins assumed to affect the import and metabolism of the mitochondrial 
dNTP precursors; on the left (C) are the supposed localization of key factors ruling 
mitochondrial dynamics (MFN2, OPA1). 
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The number of genes involved in this class of disorders has rapidly increased in the last few years, 
mostly due to the results achieved using next-generation sequencing protocols in familial and sporadic 
cases. Although the encoded proteins might display multiple catalytic activities and the functional 
characterization is incomplete for most of them, a (provisional) classification of the genes involved in 
human mtDNA instability disorders can be attempted (Table 1): 
(1) Genes encoding for key proteins of the core mtDNA replication machinery: POLG [12],  
POLG2 [13], PEO1 [14]; 
(2) Genes encoding for proteins involved in mtDNA repair and maintenance: DNA2 [15],  
MGME1 [16]; 
(3) Genes encoding for proteins preserving the mitochondrial nucleotide pool: TP [17], TK2 [18], 
DGUOK [19], SLC25A4 [7], RRM2B [20], SUCLA2 [21], SUCLG1 [22], ABAT [23]; 
(4) Genes encoding for proteins involved in mitochondrial dynamics and remodelling of 
mitochondrial membranes: OPA1 [24], MFN2 [25], FBXL4 [26,27]. 
Although mutations of some genes have been so far restricted to infantile (i.e., FBXL4) or adult  
(i.e., MGME1) presentations, novel evidence supports the concept of a genetic overlap between  
these forms, with mutations in the same gene resulting in striking differences in age of onset, tissues 
affected, progression and outcome. The reason for this heterogeneity is currently unknown. The 
hypothesis that pediatric presentations could be associated with deleterious mutations, strongly 
impacting on enzyme activity of the encoded protein, while variants disclosed in adult patients could 
preserve higher levels of residual activity, is only partially supported by experimental data [28]. The 
low levels of expression and basal activity of TK2 observed in skeletal muscle might explain the tissue 
selectivity of TK2 dysfunction, but they are not useful to understand why age of onset and progression 
are so different between infantile and adult forms [29]. Moreover, the number of pediatric and adult 
patients sharing the same molecular defects is still low, making genotype-phenotype correlations 
hazardous or not obvious. It is likely that on-going projects of massive parallel sequencing in novel 
probands featuring mtDNA instability will further expand this genetic overlap. 
The proposed classification does not include all of the genetic defects featuring muscle mtDNA 
instability. For example, although mutations in SPG7, encoding paraplegin, classically result in 
neurodegenerative diseases, such as hereditary spastic paraplegia [30] and optic neuropathies [31], 
they have been also described in patients with complex phenotypes showing prominent spastic  
ataxia with mitochondrial muscle pathology hallmarked by mtDNA deletions [32]. Similarly, 
mutations in CHCHD10 have been originally described in familial amyotrophic lateral sclerosis with 
fronto-temporal dementia [33]. Muscle biopsies of affected subjects revealed respiratory chain 
dysfunction, COX-negative fibers and a large amount of mtDNA deletions. Following this observation, 
muscle mitochondrial defects, without signs of mtDNA instability, have been observed in other 
patients presenting pure motor neuron phenotypes [34,35] or isolated mitochondrial myopathy [36]. 
The role of CHCHD10 is not completely understood: some evidence indicates that it might take part in 
mitochondrial dynamics and cristae remodelling [37]. 
In the following paragraphs, we will focus on genes associated with adult presentations featuring 
primary accumulation of mtDNA deletions in muscle. 
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Table 1. Genes involved in disorders featuring mitochondrial DNA instability. 
Pathway Gene Locus Encoded Protein Transmission Onset 
mtDNA 
Defects 
Tissues Mainly 
Affected 
Clinical 
Phenotypes 
mtDNA 
replication 
POLG 15q25 
DNA polymerase gamma,  
catalytic subunit 
AD, AR Adult dels muscle PEO, MM 
AR 
Infantile depl liver MDS, ME, AS 
Adult depl cerebellum MIRAS 
POLG2 17q 
DNA polymerase gamma,  
accessory subunit 
AD Adult dels muscle PEO 
PEO1 10q24 Twinkle 
AD Adult dels muscle PEO 
AR 
Infantile depl liver MDS 
Infantile depl brain IOSCA, ME 
mtDNA repair 
DNA2 10q21.3–q22.1 DNA replication helicase/nuclease 2 AD Adult dels muscle PEO, MM 
MGME1 20p11.23 
Mitochondrial genome  
maintenance exonuclease 1 
AR Adult dels/depl muscle PEO, MM 
dNTPs pools 
maintenance 
SLC25A4 4q35 
Adenine nucleotide  
translocator 
AD Adult dels muscle PEO 
TYMP 22q13 
Thymidine  
phosphorylase 
AR 
Late 
childhood 
Adolescence
dels/depl muscle MNGIE 
TK2 16q22–q23.1 Thymidine kinase 2 
AR 
Early 
childhood 
depl muscle MDS 
AR Adult dels muscle PEO, MM 
DGUOK 2p13 Deoxyguanosine kinase 
AR 
Neonatal 
Infantile 
depl liver/muscle MDS 
AR Adult dels muscle PEO 
RRM2B 8q23.1 
Ribonucleotide  
reductase M2 B 
AR Infantile depl muscle MDS 
AR Adult depl muscle MNGIE 
AD Adult dels muscle PEO 
SUCLA2 13q12.2–q13.1
Succinyl-CoA ligase,  
beta subunit 
AR 
Early 
childhood 
depl muscle MDS 
SUCLG1 2p11.2 
Succinyl-CoA ligase,  
alpha subunit 
AR 
Neonatal 
Infantile 
depl muscle/liver MDS 
ABAT 16p13.2 4-aminobutyrate aminotransferase AR Infantile depl brain/muscle MDS 
Mitochondrial 
dynamics 
OPA1 3q28–q29 Mitochondrial dynamin-like GTPase AD Adult dels muscle OA plus 
MFN2 1p36.22 Mitofusin 2 AR Adult dels muscle OA plus 
MPV17 2p23.2 
Mpv17 mitochondrial inner  
membrane protein 
AR 
Neonatal 
Infantile 
depl liver MDS 
AR Adult  dels brain ME 
FBXL4 6q16.1 
F-box and leucine-rich repeat  
(LRR) protein 
AR 
Neonatal 
Infantile 
depl brain/muscle ME/ 
Abbreviations: mitochondrial DNA (mtDNA), autosomal dominant (AD), autosomal recessive (AR), 
multiple mtDNA deletions (dels), mtDNA depletion (depl), progressive external ophthalmoplegia (PEO), 
mitochondrial myopathy (MM), mtDNA depletion syndrome (MDS), Alpers’ syndrome (AS), mitochondrial 
recessive ataxia syndrome (MIRAS), mitochondrial encephalopathy (ME), optic atrophy (OA), mitochondrial 
neurogastrointestinal encephalopathy (MNGIE), infantile-onset spinocerebellar ataxia (IOSCA). 
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2.1. Genes Encoding for Members of the mtDNA Replication Machinery 
The minimum replicative apparatus (replisome) of mtDNA includes the polymerase γ (POLG), the 
only DNA polymerase active within mitochondria of animal cells, the hexameric helicase Twinkle and 
the single-strand binding proteins (mtSSBPs). Other enzymatic activities, likely essential for mtDNA 
replication, include POLRMT, which supplies primers to start replication at the origin of the heavy 
strand, RNASEH1, which removes primers used during the synthesis of lagging strand, and TOP1MT, 
a 72-kDa topoisomerase, required to relax negative supercoils [38]. 
2.1.1. POLG 
The mammalian mitochondrial polymerase γ is a 250-kDa heterotrimer composed of a 140-kDa 
catalytic α subunit (encoded by human POLG) and two 55-kDa accessory β subunits (encoded by 
human POLG2) [39]. It is synthesized as a precursor containing an amino-terminal leader sequence, which 
targets the protein towards mitochondria, where the precursor is cleaved. The catalytic subunit contains  
a carboxy terminal polymerase domain (pol) and an amino terminal 3′–5′ exonuclease domain (exo) with 
proofreading activity, separated by a linker region [40]. The intrinsic exonuclease 3′–5′ function greatly 
improves the replication fidelity, and it is necessary to suppress mtDNA deletions between direct 
repetitions [41]. 
Mutations in α subunits result in pediatric- and juvenile-onset presentations such as  
Alpers–Huttenlocher syndrome (severe infantile-onset encephalopathy with epilepsy associated with 
hepatic failure), SANDO (sensory ataxic neuropathy, dysarthria and ophthalmoplegia) and MIRAS 
(mitochondrial recessive ataxia syndrome) [42]. The analysis of muscle mtDNA reveals reduced 
mtDNA content and multiple deletions. POLG mutations also constitute the most frequent cause of 
familiar (dominant or recessive) and sporadic chronic external ophthalmoplegia [12]. In recessive forms, 
peripheral neuropathy is frequent and might occur decades before ptosis; the onset is precocious 
compared to dominant forms [43]. Beside muscle, POLG mutations often strike the adult central nervous 
system with presentations including cognitive impairment, dementia and obsessive disorders [44]. POLG 
defects have been documented in different clinical presentations sharing ataxia [45]. Parkinsonism 
accompanying progressive external ophthalmoplegia (PEO), ptosis and neuropathy was also found to 
segregate with POLG mutations in a few families [44,46,47]. Therefore, POLG defects should be 
regarded as a secondary genetic cause of Parkinson’s disease, with affected patients presenting earlier 
onset and variable response to levodopa. Few reports also described premature ovarian failure with 
Parkinsonism and PEO in women harboring POLG variants [48,49]. 
The A467T mutation is the most common pathogenetic substitution in POLG, and it is estimated to 
occur in 36% of the mutated alleles. Its frequency varies between 0.2% and 1% in the general 
European asymptomatic population [50]. Almost all of the dominant POLG mutations associated with 
PEO are mapped on the polymerase domain of the enzyme. Mutated enzymes compete against  
wild-type proteins for binding to the replicative fork [51]. Experiments in S. cerevisiae displayed a 
similar behavior between human POLG mutations and the corresponding substitutions of the orthologue 
mip1: the severity of yeast phenotypes correlated with the age of onset of human presentations [52]. 
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2.1.2. POLG2 
The p55 β (accessory) subunits of polymerase γ are encoded by POLG2. They constitute a 
homodimer that binds asymmetrically to the catalytic portion of the holoenzyme (encoded by POLG). 
The proximal subunit strengthens DNA binding, while the distal subunit facilitates the nucleotide 
incorporation. The disruption of the interaction between the p55 accessory subunit and the p140 
catalytic part might promote the stalling of the replication fork and produce mtDNA deletions. 
Furthermore, POLG2 has a role in nucleoids’ structure [38,53]. 
Few pathogenetic mutations have been so far identified in POLG2 (G451E, G416A, 
c.1207_1208ins24, R369G), the patients presenting autosomal dominant ptosis and PEO with onset in 
the third to fourth decade, mild proximal muscle weakness with exercise intolerance and other 
neurologic or systemic symptoms, similarly to POLG-mutated PEO patients [13,54,55]. 
2.1.3. PEO1 
Also known as C10orf2, PEO1 encodes for a hexameric helicase of the RecA-type superfamily, 
named Twinkle. It has structural similarities with the gp4 protein of T7 phage primase/helicase. The 
linker region, important for subunit interactions and the establishment of the functional hexamer, is 
known to be a mutational hotspot for dominant PEO [14]. Apart from 5′–3′ helicase activity, Twinkle 
is essential for the maintenance and the regulation of mtDNA copy number [56]. 
Mutations that suppress Twinkle helicase activity also compromise mtDNA replication and 
transcription, since the progression of the replicative fork is hampered, causing the accumulation of 
replication intermediates [57]. The presence of a cluster of mutations in small highly-conserved regions 
supports the proposed negative-dominant behavior of Twinkle mutations on mtDNA maintenance and 
transcription [43]. As a consequence, PEO1 mutations are inherited according to an autosomal-dominant 
fashion. Heterozygous mutations might also arise de novo in sporadic patients [58]. Fratter and 
colleagues studied a cohort of 33 mutated patients (26 probands) presenting either missense mutations 
or in-frame duplications [59]. 
PEO1-mutated patients show variable onset ranging from the second to the eighth decade. Clinical 
features might include ptosis, ophthalmoparesis, proximal hyposthenia, ataxia, peripheral neuropathy, 
bulbar signs, cardiomyopathy, endocrine disorders, cataract and depression or avoiding personality tracts. 
A syndromic presentation, including sensory neuropathy with ataxia, dysarthria and ophthalmoparesis 
(SANDO), can also occur [60]. As for POLG mutations, PEO1 defects have been found to segregate 
with Parkinsonism and additional syndromic features in dominant PEO families [61,62]. Recessive 
mutations in PEO1 are less frequent and result in severe pediatric presentations, including IOSCA 
(infantile-onset spinocerebellar ataxia), mostly occurring in Finnish patients [63], and a hepatocerebral 
form of mtDNA depletion syndrome [64]. 
2.2. Genes Encoding for Factors Involved in mtDNA Repair 
The accumulation of DNA damage is thought to play a critical role in the aging process, as well as 
mitochondrial disorders [65]. It was thought for many years that mitochondria lacked an enzymatic 
DNA repair system comparable to that in the nuclear compartment. However, it is now well 
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established that DNA repair actively takes place in mitochondria, preserving genomic integrity through 
oxidative DNA damage processing, base excision repair (BER) pathways and further, still uncharacterized, 
mechanisms [66]. It is likely that the enzymatic activities required for repairing specific mtDNA 
damage might be also helpful in the processing of replication intermediates, narrowing the functional 
border between these two groups of proteins involved in mtDNA maintenance. The BER pathway 
engages the recognition and removal of deaminated, oxidized and alkylated DNA bases. Following the 
recognition of the damaged base, a group of endo/exonucleases catalyzes the consecutive steps of this 
orchestrated process. The nuclear BER has been largely explored, as well as the consequences of its 
dysfunction for human health [67]. Mammalian mitochondria also possess BER activities, promoted by 
a set of enzymes presenting double localization (nuclear and mitochondrial) or exclusively targeted to 
the mitochondrial compartment [68]. Interestingly, clinical presentations have been recently associated 
with altered mtDNA maintenance due to defective mitochondrial endo-/exo-nuclease activities. 
2.2.1. DNA2 
This gene has been recently considered as a candidate for the molecular screening of familiar  
or sporadic cases with PEO and/or myopathy accompanied by muscle accumulation of mtDNA  
deletions [15]. Human DNA2 encodes for a member of the nuclease/helicase family. It was found in 
mammalian mitochondria, where it participates in the removal of RNA primers during mtDNA 
replication [69], but exclusive mitochondrial localization is debated [70]. The encoded protein interacts 
with polymerase γ and stimulates its catalytic activity [69]. As a member of the nuclease/helicase 
family, human DNA2 contains conserved nuclease, ATPase and helicase domains. 
Experimental studies have demonstrated a role for DNA2 in the mitochondrial long patch base 
excision repair pathway primed by mtDNA defects due to oxidation, alkylation and hydrolysis. In 
particular, the nuclease activity is involved in the processing of flap intermediates occurring during the 
removal of damaged bases in BER. Inside mitochondria, this task is accomplished with the partnership 
of the flap structure-specific endonuclease 1 (FEN1). DNA2 seems also involved in the processing of 
Okazaki fragments, as demonstrated in yeast [71]. The function of DNA2 as a DNA helicase is less 
demonstrated. In yeast, helicase activity facilitates the formation of flap intermediates in vitro [72], but 
it was found to be dispensable in vivo [73]. Similarly, the mutations identified in patients and localized 
within nuclease and ATPase domains also impair helicase activity, as shown by in vitro studies [15]. 
Therefore, the helicase activity of DNA2 is also likely involved in mtDNA maintenance. At present, 
Twinkle remains the only established replicative helicase inside mitochondria. However, DNA2  
might partially support Twinkle, since it co-localizes with Twinkle in nucleoids and its mitochondrial 
recruitment is induced by PEO1 mutations [74]. 
A DNA2 homozygous out of frame truncating mutation has been identified as a genetic cause of 
Seckel syndrome [75], a disorder characterized by in utero and postnatal growth retardation, 
intellectual disability, microcephaly, facial dysmorphisms and, rarely, cardiac malformations. 
Enhanced senescence with a marked increase of damaged nuclear DNA has been observed in patients’ 
fibroblasts, supporting the hypothesis that DNA2 repair activity is affected in this disorder [75]. While 
these findings acknowledge a nuclear role for human DNA2, the striking differences between pediatric 
and adult presentations are less clear. The heterozygous mutations disclosed in adult patients impair 
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DNA2 activity less severely with respect to the homozygous truncating mutation linked with Seckel 
syndrome. Alternative nuclear and mitochondrial factors, replacing defective DNA2 and their 
differential expression among tissues, might also modulate the phenotype. 
2.2.2. MGME1 
This gene, previously known as C20orf72, encodes a RecB-type exonuclease belonging to the  
PD-(D/E)XK nuclease superfamily [76]. Cell fractioning experiments showed that the encoded polypeptide 
is targeted to mitochondria, where it is involved in mtDNA maintenance, promoting the turnover of the 
replication intermediates 7S. MGME1 cuts DNA, but not RNA or DNA-RNA hybrids; it seems to 
require free 5′-ends to exert its function (it does not work on circular DNA), and it has a greater 
affinity for single DNA than double-strand DNA in vitro. As in the case of DNA2, MGME1 also 
interacts with pol γ, therefore contributing a further 5′–3′ exonuclease activity to the mitochondrial 
machinery assembled at the replication fork [77]. 
Recessive mutations within the MGME1 coding sequence have been observed in multiple patients 
from two families and a sporadic patient. Clinical presentation includes external ophthalmoplegia, 
muscle weakness and a progressive respiratory impairment, requiring assisted ventilation [16]. 
2.3. Genes Encoding for Proteins Maintaining the Mitochondrial dNTP Pool 
As for the nuclear genome, mtDNA also require a balanced pool of dNTPs for an effective replication 
(and repair). In replicative tissues, cytosolic dNTPs, used in nuclear DNA synthesis, can be also imported 
into mitochondria through dedicated transporters, sustaining mtDNA maintenance. In non-replicative cells, 
the cytosolic de novo synthesis of dNTPs is downregulated, and the mtDNA replication, which persists  
in post-mitotic cells, relies on a set of intra-mitochondrial reactions to preserve the proportions of 
deoxyribonucleotides (dNTPs salvage pathway) [78]. Recessive mutations in key enzymes of this pathway 
might impair the supply of substrates for the mitochondrial DNA polymerase, resulting in defective 
mtDNA synthesis or increased replicative errors and genomic instability. In quiescent cells, de novo dNTP 
synthesis still partially supports the replication of mtDNA and the repair of the nuclear genome. Therefore, 
other proteins involved in nucleoside transport and metabolism might be important for mtDNA 
maintenance, as observed for the cytosolic ribonucleotide reductase (see below) [79]. Besides the obvious 
role in the supply of the “building blocks” for DNA synthesis, the deregulation of nucleotide levels might 
also have more complex consequences, overall conditioning the mitochondrial mass in the cell [80]. 
2.3.1. TYMP 
Thymidine phosphorylase (TP, encoded by TYMP, also known as ECGF1) acts as a homodimer 
catalyzing the phosphorylation of thymidine phosphate to thymidine and 2-deoxy-D-ribose 2-phosphate. 
The direct reaction is important for nucleosides catabolism, while the reverse reaction participates in 
the pyrimidine salvage pathway. 
Recessive mutations of this gene have been identified as the cause of mitochondrial neurogastrointestinal 
encephalomyopathy (MNGIE) [17]. These loss-of-function defects result in the reduction (or substantial 
absence) of thymidine phosphorylase activity and the toxic accumulation of nucleotides in plasma [17]. The 
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imbalance of the dNTP pool increases the rate of mtDNA point mutations, and both mtDNA depletion and 
deletions are observed at Southern blot analysis of muscle mtDNA. Clinical manifestations depend on 
residual TP activity. Since TP is a homodimer enzyme, the presence of a mutant allele induces 25%  
wild-type enzyme synthesis: asymptomatic heterozygotes have 25%–35% of enzymatic residual activity, 
and this threshold represents a target for therapeutic strategies, like liver transplantation, that results in  
being be six-fold more efficient as a TP source than bone marrow [81]. Neuroradiological studies in  
TYMP-mutated patients often show leukoencephalopathy [82]. Brain MRI has been suggested as a tool for 
differential diagnosis of POLG involvement in recessive PEO presentations [43]. 
2.3.2. TK2 
This gene encodes for the thymidine phosphorylase type 2, the enzyme that catalyze the rate-limiting 
step of deoxypirimidine phosphorylation within the mitochondrial dNTPs salvage pathway. The gene 
is upregulated in non-replicating cells, where the encoded product safeguards pool availability. 
TK2 deficiency has been classically associated with the myopathic form of mtDNA depletion 
syndrome, featuring an infantile-onset severe phenotype with motor regression and early death due to 
diaphragmatic paralysis [18]. Recessive mutations have been also reported in presentations resembling 
spinal muscular atrophy [83]. Mutations in the same gene have been more recently observed in adult 
phenotypes with ptosis, external ophthalmoplegia, slowly-progressive proximal muscle weakness, 
muscular atrophy and dysarthria [84,85]. In adult patients with PEO due to TK2 mutations, multiple 
deletions, but not depletion, have been found in muscle. The low basal TK2 activity in muscles could 
explain why most of the clinical features related to TK2 dysfunction affect this tissue [29]. The reason 
for the different presentations in pediatric and adult subjects is more elusive: indeed, biochemical 
studies performed in fibroblasts from adult patients with mild myopathy revealed very low TK2 
activity levels, not dissimilar to those observed in pediatric cases. 
2.3.3. DGUOK 
DGUOK encodes for the mitochondrial deoxyguanosine kinase that catalyzes the first reaction in 
the purine salvage pathway inside mitochondrial matrix. Recessive mutations have been described in 
pediatric cases showing severe encephalohepatopathy with severe reduction of liver mtDNA content 
and premature death, unless the patients undergo a liver transplant [19]. Recently, the massive parallel 
sequencing of genes encoding for established or predicted mitochondrial proteins (MitoExome) has 
revealed compound heterozygous mutations even in adult sporadic and familial forms of mitochondrial 
myopathy [28]. Muscle analysis in mutated patients disclosed mtDNA deletions with variable mtDNA 
content and significant deficiency of DGUOK protein levels and activity. The main clinical features of 
adult forms include: muscle weakness, PEO, hearing loss and bulbar signs. One of the probands 
reported had previously undergone liver transplant. Notably, two siblings harboring DGUOK 
mutations displayed an atypical phenotype characterized by slowly progressive, predominantly distal, 
upper and lower limb muscle weakness, mild dysphonia and dysphagia, similarly to SMA-like 
presentations due to TK2 deficiency. These findings clearly demonstrate that the effects of DGUOK 
and TK2 mutations are not limited to those tissues that are primarily affected in terms of severity and 
age of involvement. 
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2.3.4. SLC25A4 
This gene encodes for the ANT1 member of the ADP/ATP translocator family, localized in the 
inner mitochondrial membrane. ANT1 predominates in post-mitotic tissues, including skeletal muscle, 
heart and brain. It acts as a homodimeric gate-channel operating the ADP/ATP exchange between 
mitochondria and cytoplasm. Since ANT1 senses the adenosine concentration in the two compartments, 
it is a part of the signaling pathway coupling cellular energy consumption and mitochondrial respiratory 
chain activity [86]. Moreover, ANT1 is a structural element of the mitochondrial permeability transition 
pores (MPTP) and has a role in the intrinsic apoptotic pathway [87]. 
Heterozygous SLC25A4 mutations have been reported in patients with PEO and ptosis with or without 
generalized muscle weakness [7]. Cardiac involvement, including cardiomyopathy, disarrangement of 
myofibers, inflammation linked to heart disease and ischemic attacks [88], has been repeatedly 
described. Neurosensory hypoacusia, thyroid gout and dementia without affective aspects have also been 
reported [43]. Mutations in the same gene also result in Sengers syndrome, a multisystemic disorder 
featuring congenital cataract, hypertrophic cardiomyopathy, mitochondrial myopathy and lactic 
acidosis. Two forms are known for Sengers syndrome: a neonatal form with poor prognosis and a  
late-onset presentation with lifespan observed until the third decade [89]. 
2.3.5. RRM2B 
This gene maps on chromosome 8q22.1–q23.3 and encodes the minor subunit (p53R2) of 
ribonucleotide reductase (RNR), the tetrameric enzyme catalyzing de novo dNTPs synthesis from the 
reduction of the corresponding ribonucleosides diphosphate. RRM2B expression is tightly regulated by 
the oncosuppressor p53. In post-mitotic cells, ribonucleotide reductase contributes to mitochondrial 
dNTP supply [90], in parallel with the salvage pathway. 
Recessive mutations within the RRM2B coding sequence have been associated with the infantile 
encephalomyopathic form of mtDNA depletion syndrome [20]. In 2009, linkage analysis was used to 
drive the discovery of a heterozygous non-sense RRM2B mutation in affected members of a big North 
American family of European origin presenting adult-onset dominant PEO with muscle accumulation 
of mtDNA deletions. The same mutation in a second family was associated with additional clinical 
features, including: ataxic gait, hypoacusia, reduction of tendon reflexes and psychiatric disorders [91]. 
Kearns–Sayre syndrome (KSS) and MNGIE are rarer manifestations. RRM2B mutations were 
observed as the third most common molecular cause of PEO in a large cohort of British adult patients, 
following POLG and PEO1 [92]. The mutated or truncated protein p53R2 might compete against  
wild-type protein for the binding of heterodimeric RNR, exerting a dominant negative effect [91],  
a pathogenic mechanism compatible with defects disclosed in both pediatric and adult subjects. 
2.4. Genes Encoding for Protein Involved in Mitochondrial Dynamics and Remodeling 
It is now well established that intracellular mitochondria are organized in dynamic networks and 
physiologically undergo remodelling cycling between fission and fusion events [93]. This behavior is 
crucial for the turnover of aged mitochondria and their intracellular transport, but also compensates the 
defects accumulating in the organelle as bypass products of oxidative metabolism [94]. Together with 
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mitochondrial protein quality control system, mitochondrial dynamics have emerged as an important 
field of investigation to address the pathogenesis of human neurodegeneration. Indeed, increased 
mitochondrial fragmentation due to the reduced ratio between fusion (i.e., MFN2 and OPA1) and 
fission (i.e., DLP1/DRP1 and FIS1) proteins has been observed in tissues and cell cultures obtained 
from patients with major neurodegenerative disorders, including Alzheimer’s and Huntington’s disease. 
Furthermore, Parkinson’s disease has been associated with mutations in PARK2 and PINK1 proteins, 
which orchestrate mitochondrial protein quality control and the turnover of aged mitochondria by 
ubiquitination and degradation of MFN2 [95]. 
2.4.1. OPA1 
The product encoded by this gene is a regulatory mitochondrial fusion protein localized in the inner 
membrane, showing GTPase activity [96]. OPA1 is a main regulator of cristae morphology, but  
also plays a key role in response to cellular cytotoxic insult generated by hyperactivation of  
N-methyl-D-aspartate (NMDA) receptors for an altered homeostasis of mitochondrial calcium. Indeed, 
the increased agonism of NMDA receptors induces mitochondrial fragmentation and ultrastructural 
defects of the inner mitochondrial membrane [97]. Conversely, OPA1 overexpression is protective 
against cytotoxic glutamate response, with an increased survival of neurons and preserved mitochondrial 
morphology [98]. 
Mutations in OPA1 are the most common cause of isolated optic atrophy with dominant inheritance 
(ADOA) [99,100], as well as “plus” phenotypes where optic atrophy is accompanied by syndromic 
features, such as neurosensory deafness and ophthalmoplegia. Muscle from OPA1 plus patients  
showed signs of mitochondrial sufferance, including COX-negative fibers and accumulation of mtDNA 
deletions [24,101]. OPA1 defects not only impact retinal gangliar cells leading to the progressive 
degeneration of optic nerve, but also nervous and muscle tissues. Some studies have documented a 
compensatory increase of mtDNA copies in affected muscle fibers, independently of the severity of the 
disease [102]. The percentage of COX-negative fibers seems to be four-fold superior in the DOA plus 
form than in pure presentations. 
Recently, OPA1 sequencing in probands from two Italian families affected by dominant chronic PEO 
complicated by Parkinsonism and dementia revealed two heterozygous missense mutations affecting 
highly conserved amino acid positions in the GTPase domain [103]. Multiple mtDNA deletions were 
detected in available muscle biopsies. 
2.4.2. MFN2 
This gene encodes an outer membrane protein with GTPase activity involved in mitochondrial 
fusion. Molecular defects affecting MFN2 are a major cause of the Charcot–Marie–Tooth axonal 
neuropathy type 2A, an autosomal dominant disease characterized by a pronounced impairment of 
motor and sensory neurons [104]. 
Mutations in MFN2 have been recently disclosed in familial multisystemic disorder with optic atrophy 
beginning in early childhood, associated with axonal neuropathy and mitochondrial myopathy in adult 
life, a presentation resembling OPA1 plus phenotype. Mitochondrial DNA deletions were found in 
muscle while patients’ fibroblasts disclosed defective repair of stress-induced mtDNA damage, leading 
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to respiratory chain impairment [25]. Notably, a detrimental effect on mtDNA replication has been 
also recently documented in fibroblasts from CMT2A patients, which displayed mtDNA depletion and 
a minimal amount of deleted molecules [105], suggesting a common pathogenetic mechanism resulting 
from MFN2 dysfunction, irrespective of the clinical phenotype. 
2.4.3. MPV17 
This gene encodes for an inner mitochondrial membrane protein whose function has remained 
obscure for several years. The encoded product is a member of the family of integral membrane 
proteins comprising PXMP2, MPV17, MP-L and FKSG24 (MPV17L2) in mammals. Studies on 
vertebrates suggested a role in nucleotide trafficking between mitochondria and cytoplasm [106]. 
Recently, MPV17 was identified as a non-selective ion channel, responsible for modulation of 
mitochondrial membrane potential, which is influenced by several conditions in the organelle, such as 
redox state and protein phosphorylation [107]. 
Mutations in MPV17 have been firstly described in a severe juvenile-onset hepatoencephalopathy 
with major reduction of liver mtDNA content [108]. Coming to adult presentations, recessive MPV17 
mutations have been described in three patients presenting adult-onset multi-systemic disorders with 
neuropathy and leukoencephalopathy and featuring multiple mtDNA deletions in muscle [109–111]. 
3. Genotype-Phenotype Correlations 
Mitochondrial disorders display a spectacular clinical heterogeneity. Presentations featuring  
muscle mtDNA instability, which constitute a tiny subgroup of the spectrum of mitochondrial disorders, 
do not elude this general consideration. Indeed, the overlapping of clinical features is frequent with 
heterogeneous genetic defects resulting in undistinguishable phenotypes (Figure 2). 
 
Figure 2. Representation of clinical phenotypes related to nuclear genes involved in 
mtDNA maintenance. Abbreviations: progressive external ophthalmoplegia (PEO), 
mitochondrial recessive ataxia syndrome (MIRAS), infantile-onset spinocerebellar ataxia 
(IOSCA), sensory ataxic neuropathy, dysarthria, and ophthalmoparesis (SANDO). 
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Previous studies reporting a cohort of patients accumulating multiple mtDNA deletions in muscle 
have attempted genotype-phenotype correlations, with modest results, even considering only forms due 
to mutations in the same gene [43]. The elucidation of such correlations might be useful to speed 
molecular diagnosis. The number of candidate genes for molecular tests overcomes the resources of 
standard laboratories, even if the application of next-generation sequencing in a clinical setting is expected 
to improve the diagnostic yield, reducing the cost of genetic testing [112]. Despite these issues, some 
remarks emerge from previous studies. Patients harboring POLG mutations display severer clinical 
features and age-related penetrance, while ANT1 mutations are associated with milder phenotypes. 
PEO1 patients show clinical presentations with intermediate severity of symptoms [43]. Bulbar 
weakness, deafness and gastrointestinal symptoms are observed in TYMP [113] and RRM2B  
patients [92], favoring the analysis of these genes before more frequent defects, such as POLG  
and PEO1. Cardiac involvement, reflected by conduction defects and left hypertrophy, is more 
representative of ANT1 involvement rather than RRM2B [92]. 
Peripheral neuropathy, even if not exclusive, is often associated with POLG mutations; however,  
it also occurs in PEO1 cases [60]. Recently, a diagnostic flow-chart has been suggested for  
POLG-related diseases in pauci-symptomatic patients affected by peripheral neuropathy and suspected 
mitochondrial impairment [114]. Peripheral neuropathy has been also frequently observed in ADOA 
plus patients harboring MFN2 and OPA1 mutations [115]. 
4. Towards a Candidate-Pathway Approach 
Despite the relevant achievements gained approaching mitochondrial patients with panel or exome 
sequencing technologies [116,117], the proportion of subjects without a molecular diagnosis is still 
high. The number of phenotypes reflecting muscle mtDNA instability has increased, while the borders 
between clinical presentations are getting narrow. As for other Mendelian disorders, the application of  
next-generation sequencing techniques in a research setting led to the discovery of novel genetic  
defects [112]. Overall, in only a few years, next-generation sequencing protocols disclosed more genetic 
defects than any other strategy (linkage studies, gene-candidate approach) in the last two decades. 
Nevertheless, the number of established diagnosis only slightly increased with a global improvement in 
the diagnostic yield of around 10%. 
In the institutions where panel sequencing is routinely used for diagnostic purposes, the potential 
reduction of the time-to-diagnosis is challenged by the increased number of variants detected and the 
consequent efforts required to obtain a reliable genetic and biochemical validation. Taking into 
account these considerations, a detailed clinical assessment and a more accurate (or extended) 
genotyping performance might be important, but not decisive advancements. Conversely, the 
identification of clinical and molecular features shared by patients presenting defects in the same 
functional pathway, accompanied by quantitative measurements of deleted mtDNA molecules in muscle 
samples, could be used to drive the selection of genes or pathways to be addressed in molecular 
testing, improving the diagnosis of single patients in a short timeframe. 
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